Neoadjuvant chemotherapy and pathologic response: a retrospective cohort

Area of Science:

• Oncology
• Medical Research

Background:

• Locally advanced breast cancer (LABC) requires effective neoadjuvant chemotherapy.
• The doxorubicin/cyclophosphamide regimen followed by paclitaxel is a common treatment protocol.

Purpose of the Study:

• To evaluate the pathologic complete response (pCR) rate in LABC patients treated with neoadjuvant doxorubicin/cyclophosphamide followed by paclitaxel.
• To identify factors influencing pCR in this patient cohort.

Main Methods:

• Retrospective cohort study of 434 LABC patients treated between 2006-2008.
• Patients received 4 cycles of doxorubicin/cyclophosphamide followed by 4 cycles of paclitaxel.
• Data collected included patient demographics, tumor characteristics, treatment details, toxicity, and pathologic response.

Main Results:

• 17.1% of patients achieved a pathologic complete response (pCR).
• Median tumor size decreased from 65mm to 22mm.
• Patients with a negative hormonal profile or triple-negative status (HER2-negative, hormone receptor-negative) had a favorable impact on pCR.

Conclusions:

• Neoadjuvant chemotherapy with doxorubicin/cyclophosphamide followed by paclitaxel is effective in achieving pCR in LABC patients.
• Triple-negative breast cancer patients demonstrate a higher probability of achieving pCR with this regimen.